Business Context and Reporting Period
This Form 8-K Current Report from Disc Medicine, Inc. (Nasdaq: IRON) covers the period ending June 12, 2023. The filing announces the entry into a material definitive agreement for a public offering of common stock and pre-funded warrants.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 2,595,919 shares of Common Stock at $49.00 per share and 204,081 Pre-Funded Warrants at $48.9999 per warrant.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 420,000 shares of Common Stock.
- Expected Net Proceeds: Approximately $128.2 million, or approximately $147.6 million if the over-allotment option is exercised in full.
- Underwriters: Morgan Stanley & Co. LLC, SVB Securities LLC, Stifel, Nicolaus & Company, Incorporated, and BMO Capital Markets Corp.
- Closing Date: Expected on June 16, 2023.
Material Changes and Transaction Terms
The primary material change is the execution of the Underwriting Agreement dated June 13, 2023. Key terms include:
- Pre-Funded Warrants: Immediately exercisable at $0.0001 per share or via cashless exercise. The Company does not intend to list these warrants on any exchange.
- Ownership Limits: Holders are restricted from exercising warrants if it results in beneficial ownership exceeding 24.99% of outstanding shares, unless they elect a lower initial limit (4.99%, 9.99%, or 19.99%).
- HSR Thresholds: Exercise may be limited if it triggers Hart-Scott-Rodino Antitrust Improvements Act filing requirements.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue forecasts, or management commentary regarding future operational performance. The document focuses on the mechanics of the capital raise. Risks associated with the transaction include customary closing conditions and regulatory approvals related to the HSR Act.
Investor Verification Checklist
- Verify the final closing of the offering on or after June 16, 2023.
- Confirm whether the underwriters exercised the option to purchase the additional 420,000 shares.
- Review the final prospectus supplement (filed June 15, 2023) for updated use of proceeds.
- Monitor the Company's cash position post-closing to assess runway extension.